MeMed Raises $93M To Decode Body’s Immune Response
MeMed has developed an immune-based protein signature, which distinguishes between bacterial and viral infections.
January 11, 2022
Israel’s NeoTx Raises $45M For Cancer Immunotherapy Treatment
The Rehovot-based company uses its Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies.
February 20, 2020